Last reviewed · How we verify
Baker's yeast (Bio Chromium)
Baker's yeast enriched with chromium enhances insulin sensitivity and glucose metabolism by providing bioavailable chromium that potentiates insulin signaling.
Baker's yeast enriched with chromium enhances insulin sensitivity and glucose metabolism by providing bioavailable chromium that potentiates insulin signaling. Used for Type 2 diabetes mellitus, Glucose metabolism disorders.
At a glance
| Generic name | Baker's yeast (Bio Chromium) |
|---|---|
| Sponsor | Medical Research Foundation, The Netherlands |
| Drug class | Nutritional supplement / Chromium compound |
| Target | Insulin receptor signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Metabolic Disorders |
| Phase | Phase 3 |
Mechanism of action
Bio Chromium is a chromium-enriched baker's yeast preparation designed to improve glycemic control by enhancing insulin receptor function and glucose uptake in peripheral tissues. Chromium acts as a cofactor for insulin signaling pathways, potentially improving glucose homeostasis in metabolic disorders. The yeast matrix may enhance bioavailability and tolerability of the chromium.
Approved indications
- Type 2 diabetes mellitus
- Glucose metabolism disorders
Common side effects
- Gastrointestinal disturbance
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: